Results 201 to 210 of about 124,795 (370)
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source
Microsatellite instability in early sporadic breast cancer
Jacqui Shaw+5 more
openalex +1 more source
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma [PDF]
Helga B. Salvesen+6 more
openalex +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source
Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors
We investigated the genomic profiles of patients with skin melanoma who had received immune checkpoint inhibitors and explored associations with clinical features and outcomes via a large‐scale nationwide database in Japan (the C‐CAT database). Patients with multiple (two or more) liver metastases or brain metastases were more likely to have NOTCH3 or ...
Yao Liang+4 more
wiley +1 more source
Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. [PDF]
Awosika JA, Gulley JL, Pastor DM.
europepmc +1 more source
Microsatellite instability in Japanese gastric cancer
Hideaki Nakashima+5 more
openalex +1 more source
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status [PDF]
Rui Bras-Gonçalves+5 more
openalex +1 more source
Focusing on differences in immunogenicity, we analyzed the immune microenvironment specific to cancer with high immunogenicity and found that CXCL9 and CXCL13 are associated with the formation of an activated immune microenvironment around cancer with high immunogenicity through the formation of TLS.
Yoshihiro Nagase+9 more
wiley +1 more source
Microsatellite Instability in the Tumor Microenvironment: The Role of Inflammation and the Microbiome. [PDF]
Vargas-Castellanos E, Rincón-Riveros A.
europepmc +1 more source